Oxybate ( DrugBank: Oxybate )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	3
149	Hemiconvulsion hemiplegia epilepsy syndrome	1

6. Parkinson disease

---

Clinical trials : 2,298 /  Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04006925 (ClinicalTrials.gov)	September 10, 2019	27/6/2019	Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate	Sodium Oxybate in Treatment-Resistant REM Sleep Behavior Disorder (RBD): A Randomized Placebo-Controlled Trial	REM Sleep Behavior Disorder;Parkinson Disease	Drug: Sodium Oxybate;Other: Placebo	Stanford University	Jazz Pharmaceuticals	Recruiting	40 Years	85 Years	All	24	Phase 4	United States
2	NCT02111122 (ClinicalTrials.gov)	April 2014	8/4/2014	Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease	A Phase II, Prospective, Randomized, Double-blind, Crossover Placebo-controlled Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease	Sleep-wake Disturbances in Motor-phase Parkinson's Disease	Drug: Sodium Oxybate;Drug: Placebo	Christian Baumann	NULL	Completed	18 Years	90 Years	All	16	Phase 2	Switzerland
3	NCT00641186 (ClinicalTrials.gov)	September 2004	18/3/2008	Trial of Xyrem for Excessive Daytime Sleepiness and Sleep Disturbance in Parkinson's Disease (PD)	A Phase II, Eight Week, Multi-Center, Open Label Trial of Xyrem(R) (Sodium Oxybate) for Excessive Daytime Sleepiness and Nocturnal Sleep Disturbance in Patients With Mild to Moderate Parkinson's Disease	Parkinson Disease	Drug: sodium oxybate	Baylor College of Medicine	Jazz Pharmaceuticals	Completed	30 Years	75 Years	Both	30	Phase 2	NULL

149. Hemiconvulsion hemiplegia epilepsy syndrome

---

Clinical trials : 25 /  Drugs : 40 - (DrugBank : 14) / Drug target genes : 17 - Drug target pathways : 20

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00931164 (ClinicalTrials.gov)	August 2009	30/6/2009	Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO)	Single-center Phase I/II Trial of Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO Trial)	Alternating Hemiplegia of Childhood	Drug: Sodium Oxybate	University of Utah	Alternating Hemiplegia of Childhood Foundation;Jazz Pharmaceuticals	Completed	6 Months	25 Years	All	6	Phase 1/Phase 2	United States